Immutep Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Immutep kazanç ve gelirin sırasıyla yıllık 38.6% ve 51.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 4.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -75.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

38.6%

Kazanç büyüme oranı

4.1%

EPS büyüme oranı

Biotechs kazanç büyümesi	15.2%
Gelir büyüme oranı	51.8%
Gelecekteki özkaynak getirisi	-75.1%
Analist kapsamı	Low
Son güncelleme	04 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

May 19

Kazanç ve Gelir Büyüme Tahminleri

ASX:IMM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	42	-50	-77	-39	3
6/30/2026	5	-68	-76	-76	3
6/30/2025	5	-63	-82	-68	3
6/30/2024	4	-43	-36	-35	N/A
3/31/2024	4	-42	-39	-38	N/A
12/31/2023	4	-41	-42	-42	N/A
9/30/2023	4	-40	-39	-39	N/A
6/30/2023	4	-40	-35	-35	N/A
3/31/2023	4	-38	-33	-33	N/A
12/31/2022	4	-37	-30	-30	N/A
9/30/2022	5	-34	-30	-30	N/A
6/30/2022	5	-32	-30	-30	N/A
3/31/2022	4	-29	-25	-25	N/A
12/31/2021	4	-26	-20	-20	N/A
9/30/2021	4	-28	-19	-19	N/A
6/30/2021	4	-30	-18	-18	N/A
3/31/2021	5	-29	-16	-16	N/A
12/31/2020	6	-27	-15	-15	N/A
9/30/2020	10	-20	-13	-13	N/A
6/30/2020	14	-13	-11	-11	N/A
3/31/2020	13	-15	-13	-13	N/A
12/31/2019	13	-16	-14	-14	N/A
9/30/2019	9	-17	-15	-15	N/A
6/30/2019	6	-18	-15	-15	N/A
3/31/2019	5	-18	-13	-13	N/A
12/31/2018	5	-17	-10	-10	N/A
9/30/2018	6	-15	-9	-9	N/A
6/30/2018	7	-13	-8	-8	N/A
3/31/2018	6	-12	N/A	-8	N/A
12/31/2017	7	-10	N/A	-8	N/A
9/30/2017	5	-9	N/A	-8	N/A
6/30/2017	4	-9	N/A	-9	N/A
3/31/2017	3	-10	N/A	-8	N/A
12/31/2016	2	-10	N/A	-9	N/A
9/30/2016	2	-36	N/A	-10	N/A
6/30/2016	2	-62	N/A	-11	N/A
3/31/2016	2	-71	N/A	-10	N/A
12/31/2015	1	-82	N/A	-8	N/A
9/30/2015	1	-57	N/A	-8	N/A
6/30/2015	1	-32	N/A	-8	N/A
3/31/2015	1	-23	N/A	-10	N/A
12/31/2014	1	-14	N/A	-13	N/A
9/30/2014	2	-14	N/A	-13	N/A
6/30/2014	2	-13	N/A	-14	N/A
3/31/2014	2	-13	N/A	-14	N/A
12/31/2013	2	-13	N/A	-14	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IMM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: IMM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: IMM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: IMM şirketinin gelirinin (yıllık 51.8% ) Australian pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: IMM şirketinin gelirinin (yıllık 51.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IMM 3 yıl içinde kârsız olması bekleniyor.

Immutep Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 64%

Consensus revenue estimates increase by 16%

No longer forecast to breakeven

No longer forecast to breakeven

Price target increased by 8.1% to AU$0.97

Price target decreased by 29% to AU$0.90

Recent updates

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Consensus revenue estimates increase by 64%

Consensus revenue estimates increase by 16%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

New minor risk - Shareholder dilution

No longer forecast to breakeven

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Price target increased by 8.1% to AU$0.97

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

New minor risk - Profitability

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Price target decreased by 29% to AU$0.90

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 54%

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Consensus EPS estimates upgraded to AU$0.024 loss

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Consensus EPS estimates fall by 58%

Immutep Limited, Annual General Meeting, Oct 24, 2023

Consensus revenue estimates decrease by 77%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to AU$0.052 loss

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 23%

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Consensus revenue estimates increase by 19%

Price target increased by 15% to AU$1.33

No longer forecast to breakeven

Consensus revenue estimates increase by 20%

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Consensus forecasts updated

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Less than half of directors are independent

Consensus forecasts updated

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Consensus forecasts updated

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director